LOW DOSE REGIMEN AND FORMULATION OF A 5-METHYL-1,2,4-OXADIAZOL-3- YL COMPOUND

ABSTRACT The present invention provides a compound of Formula I:, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a ne...

Full description

Saved in:
Bibliographic Details
Main Authors MERGOTT Dustin James, KIELBASA William Brian
Format Patent
LanguageEnglish
Spanish
Published 01.03.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:ABSTRACT The present invention provides a compound of Formula I:, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a neurodegenerative disease, including neurodengenerative tauopathies, such as Alzheimers disease, frontotemporal dementia, corticobasilar syndrome, and progressive supranuclear palsy. La presente invención proporciona un compuesto de Fórmula I: (ver Fórmula), o una sal farmacéuticamente aceptable de este, en donde el compuesto de Fórmula I, o una sal farmacéuticamente aceptable de este, se administra por vía oral con una dosis total del compuesto de 0.1 mg/día a 5 mg/día, y es útil para tratar una enfermedad neurodegenerativa, incluidas las tauopatías neurodegenerativas, como la enfermedad de Alzheimer, la demencia frontotemporal, el síndrome corticobasilar y la parálisis supranuclear progresiva.
Bibliography:Application Number: MX20230000993